For a comprehensive and interactive experience, please explore the full Multichannel News Release by clicking on this link: [link to the release]
In a recent engaging video presentation, La La delves into the impact of plaque psoriasis on her personal and professional life. She emphasizes the importance of advocating for treatment options that are convenient and effective for individuals with the condition. La La shares her journey of trying various methods to manage plaque psoriasis, highlighting the need for open dialogue with healthcare providers about treatment preferences and lifestyle constraints.
Plaque psoriasis, often misunderstood as a skin condition, is actually an autoimmune disease characterized by inflammatory patches that can be itchy and flaky. Research indicates a discrepancy between patients and doctors in assessing the severity of the condition, with patients often perceiving it to be more severe than medical evaluations.
While topical treatments like creams and ointments are commonly prescribed for plaque psoriasis, they primarily address symptoms rather than the underlying inflammation. Many patients find these treatments messy and inconvenient to apply. Dermatologists emphasize the importance of individualized treatment plans that consider disease severity and lifestyle factors.
To engage with La La’s insightful video, gain resources for facilitating discussions about plaque psoriasis treatment with healthcare professionals, and learn about treatment options like Otezla (apremilast), please visit MomentsWithLaLa.com. It’s important to note that La La is currently not undergoing treatment with Otezla.
Amgen is dedicated to supporting individuals with plaque psoriasis by ensuring affordable access to Otezla. For more information, please visit the official Otezla website.
Psoriasis is a chronic condition characterized by the rapid buildup of skin cells, resulting in red, scaly, and itchy patches. Globally, over 125 million people, including more than 8 million in the United States, are affected by psoriasis, with approximately 80% having plaque psoriasis.
Otezla (apremilast) is an oral medication that inhibits phosphodiesterase 4, leading to increased levels of cAMP, which may modulate inflammatory mediator production. Since its FDA approval in 2014, Otezla has been prescribed to over 1 million patients worldwide for various indications, including plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease.
Please refer to the full Prescribing Information for Otezla for detailed safety information and contraindications.
Amgen is a leading biotechnology company committed to developing innovative medicines to combat challenging diseases. With a focus on cancer, heart disease, osteoporosis, inflammatory conditions, and rare diseases, Amgen remains at the forefront of scientific advancement in the biopharmaceutical industry. Amgen has received accolades for its innovation and is recognized as one of the top companies in industry indices like the Dow Jones Industrial Average and Nasdaq-100.
For more information about Amgen and its initiatives, please visit their official website and follow them on social media platforms like Twitter, LinkedIn, Instagram, TikTok, YouTube, and Threads.
For further inquiries or media contact, please reach out to Amgen representatives: Elissa Snook at 609-251-1407 (media), Breen Weir at 415-535-9814 (media), and Justin Claeys at 805-313-9775 (investors).
Source: Amgen
References:
1. National Psoriasis Foundation. About Psoriasis. Accessed September 10, 2024.
2. National Psoriasis Foundation. Plaque Psoriasis. Accessed September 10, 2024.
